Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Novel Anti-Thrombotic Mechanism: Investigating Platelet Alpha-Dystrogylcan Induced Signalling in Thrombosis
EF 2022-23
Résumé
Cardiovascular diseases mediated by clotting events or thrombosis are a leading cause of death worldwide. Platelets are cells in the blood that are important for stopping bleeding. These versatile and essential cells must be activated by special conditions in the bloodstream which normally occur upon blood vessel injury. Proteins such as integrin and glycoproteins are important for this activation and subsequent aggregation of platelets. Interestingly, patients with a genetic disease known as Duchenne muscular dystrophy (DMD) where a protein known as alpha-dystroglyan (?DG) is mutated are reported to suffer from excessive bleeding. This suggests a role of ?DG in stopping bleeding, however, this role has never been previously explored. Our lab has found that platelet aggregation is significantly reduced when we block ?DG on the surface of platelets. Furthermore, we have recently detected a novel binding interaction between ?DG and an important platelet activation protein known as GPIb?. We hypothesize that ?DG is a crucial ligand for platelet signalling and regulates platelet activation, aggregation, and thrombosis. We plan to investigate our hypothesis by screening for additional novel binding partners of ?DG with biophysical detection techniques. We will also clarify the signalling role ?DG has and how it relates to platelet activation by assessing if ?DG signalling is reduced when platelet activation is reduced. We will also investigate ?DG gene knockout mouse model which will allow us to better characterize the risks of patients with DMD. Our findings will identify a key mechanism involved in thrombosis to improve care for DMD patients, promote novel anti-thrombotic drug development, and reveal new ways of regulating platelets in inflammation and cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486262
Name
Prifti Viktor
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel Anti-Thrombotic Mechanism: Investigating Platelet Alpha-Dystrogylcan Induced Signalling in Thrombosis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aggregation; Alpha-Dystroglycan; Cardiovascular; Integrin; Ligands; Muscular Dystrophy; Platelets; Protein Glycosylation; Signalling; Thrombosis
Abstract
Cardiovascular diseases mediated by clotting events or thrombosis are a leading cause of death worldwide. Platelets are cells in the blood that are important for stopping bleeding. These versatile and essential cells must be activated by special conditions in the bloodstream which normally occur upon blood vessel injury. Proteins such as integrin and glycoproteins are important for this activation and subsequent aggregation of platelets. Interestingly, patients with a genetic disease known as Duchenne muscular dystrophy (DMD) where a protein known as alpha-dystroglyan (?DG) is mutated are reported to suffer from excessive bleeding. This suggests a role of ?DG in stopping bleeding, however, this role has never been previously explored. Our lab has found that platelet aggregation is significantly reduced when we block ?DG on the surface of platelets. Furthermore, we have recently detected a novel binding interaction between ?DG and an important platelet activation protein known as GPIb?. We hypothesize that ?DG is a crucial ligand for platelet signalling and regulates platelet activation, aggregation, and thrombosis. We plan to investigate our hypothesis by screening for additional novel binding partners of ?DG with biophysical detection techniques. We will also clarify the signalling role ?DG has and how it relates to platelet activation by assessing if ?DG signalling is reduced when platelet activation is reduced. We will also investigate ?DG gene knockout mouse model which will allow us to better characterize the risks of patients with DMD. Our findings will identify a key mechanism involved in thrombosis to improve care for DMD patients, promote novel anti-thrombotic drug development, and reveal new ways of regulating platelets in inflammation and cancer.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Prifti, Viktor
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~